NY-AQARA
3.11.2022 09:01:35 CET | Business Wire | Press release
Aqara, a leading provider for smart home products, shares its latest plan of Matter support and integration for its existing and new devices. Aqara is fully committed to supporting Matter, and the Company has been working with the Connectivity Standards Alliance (CSA) and key stakeholders such as Apple, Google and Samsung on early testing programs to ensure a smooth transition towards the new standard. Aqara users will first gain access to Matter in December 2022 via the Aqara Hub M2 through an OTA (over-the-air) update, which will allow existing Aqara Zigbee devices to become compatible with Matter.
Other Aqara hubs, including the Hub M1S/M1S Gen 2, Hub E1, Camera Hub G3, and Camera Hub G2H Pro, will also receive similar OTA updates in the following months so that more Aqara users will be able to enjoy the benefits of Matter. The software updates are expected to first expose more than 40 Aqara Zigbee devices ranging from smart sensors and wireless switches to controller-type devices such as radiator thermostats and curtain controllers*. Through the Aqara hubs, these devices will be able to support Matter and connect with other third-party Matter devices. Some of these devices are listed below:
- Door & Window Sensor
- Temperature & Humidity Sensor
- Motion Sensor and Motion Sensor P1
- Vibration Sensor
- Smart Wall Switch (US)
- Smart Wall Switch H1 EU
- Smart Plug (US & EU)
- Single Switch Module T1
- Wireless Mini Switch
- Wireless Remote Switch H1
- Wireless Remote Switch (Single & Double Rocker)
- Radiator Thermostat E1
- Roller Shade Driver E1
- Curtain Driver E1
- Roller Shade Controller (Zigbee 1.2)
- LED Bulb and LED Bulb T1 (Tunable White)
Aqara aims to provide a comprehensive suite of Matter-compatible devices to global users, and its Matter device portfolio will continue to grow and incorporate other existing Zigbee devices in the coming future. Ultimately more than 160 Aqara Zigbee products belonging to over 10 different device categories are expected to receive Matter support.
Moreover, a new lineup of Thread-based devices will be introduced. Building upon the success of Aqara’s iconic door and window sensor as well as the motion sensor, the Company will refresh the designs of these two devices to adopt the Thread protocol - among other enhancements - to allow for native Matter support and direct connection with Matter controllers. The new sensors, i.e. the Door and Window Sensor P2 and the Motion and Light Sensor P2, are set to release in early 2023. As part of the ongoing partnership between NXP Semiconductors and Aqara, the Aqara Thread sensor will be showcased at the NXP demo table on the Matter launch event in Amsterdam.
An array of Thread-based Aqara devices is to follow including various smart sensors, dimmer switches, smart plugs, lights, and the next-gen smart home hub with multi-protocol support. The Aqara Hub M3 is designed to not only allow Aqara Zigbee devices to support Matter, but also serve as a Thread Border Router and a Matter Controller and Commissioner, which can directly connect and manage Thread and Matter-compatible smart home devices. The Company also plans to open its Aqara Home app to support third-party Matter devices.
Aqara strives to offer high-quality, smart home solutions that are accessible to everyone, specifically focusing on creating a seamless user experience. The Matter standard undoubtedly raises connected home experiences to the next level with unprecedented interoperability and simplicity, and Aqara will continue to enrich its Matter portfolio to offer users even more options for their smart homes and to expedite the mass adoption of smart homes worldwide.
* A full list of the first Aqara Zigbee devices to receive Matter support is available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom